Market
Story
![FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment](/_next/image?url=https%3A%2F%2Fmedia.deepnewz.com%2Fimages%2Ffda-approves-january-26-2025-monthly-maintenance-dosing-eisai-biogen-s-lecanemab-11d15149%2F78d5cf8ec707c389c2ccfa5d5af41339be97930d31ab395cd25f74015bec7571.jpeg&w=3840&q=75)
FDA Approves January 26, 2025, Monthly Maintenance Dosing for Eisai/Biogen's lecanemab-irmb in Early Alzheimer's Treatment
Jan 27, 2025, 02:46 AM
The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease. This decision, announced on January 26, 2025, allows for intravenous administration of the drug developed by Eisai Co. Ltd. and Biogen. The approval signals a significant advancement in the treatment options available for early-stage Alzheimer's patients, providing a new avenue for ongoing management of the disease.
View original story
Similar markets
More than $2 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
$1 billion to $1.5 billion • 25%
Less than $1 billion • 25%
Exceeds $2 billion • 25%
$1.5 billion to $2 billion • 25%
$1 billion to $2 billion • 25%
$2 billion to $3 billion • 25%
More than $3 billion • 25%
Less than $1 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Other • 25%
No clear leader • 25%
Eli Lilly • 25%
Eisai/Biogen • 25%
Less than 10% • 25%
More than 30% • 25%
21% to 30% • 25%
10% to 20% • 25%